Most solid tumor cancers including pancreatic, colorectal, and kidney originate from cells that exhibit stem-like features. These include the capacity to renew themselves indefinitely, give rise to all of the cell types within the tumor, and are responsible for the uncontrolled growth of cancer cells. These cells are resistant to most radio/chemo and even newer immunotherapies and are responsible for tumor relapse. These cells also evade the patient’s own immune system thereby preventing the tumor-killing activity of macrophages, natural killer cells, and cytotoxic key lymphocytes(immunosuppression). These cells contribute to metastasis via a process known as epithelial-to-mesenchymal transition (EMT). COARE Holdings has patented and patent-pending therapeutics designed to block cancer initiation, progression, and metastasis and reactivate host anti-tumor immunity.
- Most solid tumor cancers including pancreatic, colorectal and kidney originate from cells that exhibit stem-like features
- These include the capacity to renew themselves indefinitely, give raise to all of cell types within the tumor and are responsible for the uncontrolled growth of cancer cells
- These cells are resistant to most radio/chemo and even newer immunotherapies and are responsible for tumor relapse
- These cells also evade the patient’s own immune system thereby preventing tumor killing activity of macrophages, natural killer cells and cytotoxic key lymphocytes (immunosuppression)
- These cells contribute to metastasis via a process known as epithelial-to-mesenchymal transition (EMT)
- COARE Biosciences, a wholly owned subsidiary of COARE Holdings has patented and patent-pending therapeutics designed to block cancer initiation, progression and metastasis and reactivate host anti-tumor immunity
LIKE WHAT YOU SEE?